LYTGOBI

• tagApproval12 co-mentions · 3 sources
• drugfutibatinib12 co-mentions · 3 sources
• companyTaiho Oncology Inc6 co-mentions · 3 sources
• tagOncology6 co-mentions · 3 sources
• tagSmall Molecule6 co-mentions · 3 sources

Trials studying LYTGOBI

• phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancerrecruitingn=4,200
• phase2Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumorsactive not recruitingn=53
• phase3Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.enrolling by invitationn=15
• phase1Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplificationsactive not recruitingn=85
• phase2Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinomaterminatedn=43
• phase2A Study of TAS-120 in Patients With Metastatic Breast Cancerterminatedn=64
• phase2Futibatinib in Patients With Specific FGFR Aberrationsterminatedn=115
• phase3Personalized Medicine for Advanced Biliary Cancer Patientsrecruitingn=800